Mutations in the genes encoding the cytoplasmic and mitochondrial forms of isocitrate
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …

The immune systems of post-pubescent males and females differ significantly with profound
consequences to health and disease. In many cases, sex-specific differences in the immune …

Patients with acute myeloid leukaemia (AML) often achieve remission after therapy, but
subsequently die of relapse that is driven by chemotherapy-resistant leukaemic stem cells …

Refractoriness to induction chemotherapy and relapse after achievement of remission are
the main obstacles to cure in acute myeloid leukaemia (AML). After standard induction …

Abstract Treatment results for patients with newly diagnosed FMS-like tyrosine kinase 3
(FLT3)-mutated (FLT3 mut+) acute myeloid leukemia (AML) ineligible for intensive …

Acute myeloid leukemia (AML) is an aggressive cancer with a poor prognosis, for which
mainstream treatments have not changed for decades. To identify additional therapeutic …

Therapy resistance is a major challenge in the treatment of cancer. Here, we performed
CRISPR-Cas9 screens across a broad range of therapies used in acute myeloid leukemia to …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. The
pathophysiology of this disease is just beginning to be understood at the cellular and …

Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. AML is
a heterogeneous malignancy characterized by distinct genetic abnormalities. Recent …

Acute myeloid leukemia (AML) is a devastating disease, with the majority of patients dying
within a year of diagnosis. For patients with relapsed/refractory AML, the prognosis is …